Related Experiment Video
Updated: Apr 15, 2026
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
21.9K
[Non-muscle-invasive high-grade bladder cancer]
1Klinik und Poliklinik für Urologie, Eberhard-Karls-Universität Tübingen, Tübingen, Deutschland.
Der Urologe. Ausg. A
|March 25, 2015
Summary
Non-muscle-invasive bladder cancer poses challenges. Bacillus Calmette-Guèrin (BCG) intravesical therapy is standard for bladder preservation, while photodynamic diagnostics aid in high-grade tumor resection.
Area of Science:
- Urology
- Oncology
Context:
- Non-muscle-invasive bladder cancer (NMIBC) with low-grade differentiation presents unique clinical challenges.
- Current diagnostic and therapeutic strategies for NMIBC require careful consideration of tumor grade and invasion depth.
Purpose:
- To review current standards of care and emerging techniques for managing non-muscle-invasive bladder cancer.
- To highlight the role of Bacillus Calmette-Guèrin (BCG) therapy and advanced diagnostic modalities.
Summary:
- Urine cytology remains a key diagnostic marker, though photodynamic diagnostics are crucial for transurethral resection of the bladder (TURB) in high-grade T1 tumors.
- Histopathological assessment of T1 tumors can be enhanced with substaging and invasion pattern analysis.
- Intravesical BCG therapy is the gold standard for bladder preservation and maintenance therapy, while cystectomy is a safe option for high-grade bladder cancer.
Impact:
- Optimizing treatment strategies for NMIBC can improve patient outcomes and preserve bladder function.
- Integration of advanced diagnostic tools and standardized therapeutic protocols can enhance the management of bladder cancer.
